Skip to main content
. 2017 Nov 30;101(6):995–1005. doi: 10.1016/j.ajhg.2017.10.009

Table 1.

Comparison of Clinical Features of Affected Individuals with the p.Arg913Ter or p.Arg1163Trp ZSWIM6 Variants

ZSWIM6 Variant/Affected Individual p.Arg913Ter Affected Individual 1 p.Arg913Ter Affected Individual 2 p.Arg913Ter Affected Individual 3 p.Arg913Ter Affected Individual 4 p.Arg913Ter Affected Individual 5 p.Arg913Ter Affected Individual 6 p.Arg913Ter Affected Individual 7 Summary p.Arg913Ter Cohort (n = 7) Summary Postnatal Non-mosaicap.Arg1163Trp Cohort (n = 6)
Method of testing and confirmation WGS of proband, SS to confirm and segregate in family Trio WES, SS confirmation WES of proband, SS to confirm and segregate in family WES of proband, SS to confirm and segregate in family WES of proband, SS to confirm and segregate in family trio WGS, SS to confirm and segregate in family trio WES, SS confirmation
Inheritance, if known; parental ages at birth of child not maternal;b paternal 32, maternal 32 DN; paternal 31, maternal 28 DN; paternal 34,maternal 25 DN DN; paternal 33, maternal 32 DN; paternal 32, maternal 31 DN; paternal 30, maternal 29 6/7 DN; 1/7 unknown 4/6 DN; 1 NT; 1/6 inherited from mosaic parent
Evidence of mosaicism? (wild-type: mutant reads) no (32:22) no (75:62) no (121/257) no (99/191) no (69/165) no (50:50) no (24:25)
Age (year) 16 7 4 5 3 29 29 3–29 years unknown
Gender M F F F F M M 3/7 male (43%) 4/6 male (67%)
Level of ID severe-profound severe severe severe severe profound severe 7/7 severe-profound (100%) 6/6 severe (100%)
OFC normo-cephaly progressive microcephaly (−2 SD) progressive microcephaly normocephaly progressive microcephaly progressive macro-cephaly to 90–97th centile normo-cephaly progressive microcephaly 3/7 (43%); progressive macrocephaly 1/7 (14%) NR
Infantile hypotonia/delayed GM milestones? + + + + + + + 7/7 (100%) 6/6 (100%)
ASD? + + + + + 5/7 (71%) NR
Communication non verbal non verbal; limited comprehension gestures; non verbal few words; PECS babble and one word (no); starting to use PECS vocalizes, one sign short sentences, articulation difficulties 6/7 non-verbal or only few words (86%) 2/2 non-verbal (100%)
Ambulation non ambulant (wheelchair); previously ambulant at 2.5 yr with wide unsteady gait ambulant (from 3 year) with wide-based ataxic gait ambulant with wide unsteady gait (from 2 year) ambulant with wide unsteady gait, stroller used for distances starting to cruise ambulant with wide-based gait; wheelchair for distances ambulant with broad-based unsteady gait 5/7 ambulant (71%) with wide-based gait 2/2 non ambulant (100%)
Temperament/behavior happy, affectionate, interested in family and TV; hyperactivity happy; bursts of laughter; hyperactivity happy; hyperactivity; repetitive behaviors; pica interactive and sociable no behavioral concerns happy, affectionate; loves music and water play happy; hyperactivity and attention deficit; history of pica 4/7 hyperactivity (57%) NR
Epilepsy + (GTC and focal dyscognitive) (under investigation for starting episodes and unusual movements) + (IS: controlled with medication) + (infrequent GTC and absence from age 9) + possible absence seizures (no medication) 4/7 seizure/possible seizure disorder (57%) 1/6 (17%)
Progressive spasticity + + + 3/7 (43%) NR
Movement disorder? paroxysmal hypertonicity; unusual tongue movements stereotypical hand movements; midline tongue protrusion; ataxia paroxysmal hypertonicity; unusual tongue movements; ataxia body rocking; ataxia stereotypical hand movements; ataxia ataxia, tongue thrusting, head tics 6/7 (86%) NR
Ophthalmological features impairment lateral gaze strabismus accommodative esotropia right sided esotropia right sided esotropia 5/7 (71%) variable: cataract, glaucoma, myopia, optic nerve hypoplasia
Brain MRI cortical atrophy (13 year) normal normal normal (7 mo) normal mild cortical atrophy (22 mo) but later MRI considered normal normal cortical atrophy 1/7 (14%) interhemispheric lipoma 6/6 (100%); abnormal corpus callosum 3/6 (50%); other abnormalities variable
Additional neurological features mixed peripheral neuropathy truncal hypotonia, abnormally high pain threshold truncal hypotonia bilateral ankle pronation and toe pointing, torticollis full neurological examination not possible abnormally high pain threshold, self-sustained injuries 5/7 (71%) NR
Gastro-intestinal symptoms failure to thrive and severe GERD requiring fundoplication; constipation; ulcerative colitis from mid-teens infantile cow’s milk protein intolerance; recurrent diarrhea and vomiting from 18 mo improved on gluten-free diet GERD severe GERD requiring gastrostomy GERD and failure to thrive intermittent constipation 6/7 (86%) significant GI symptoms NR
Additional non- neurological features marked equinovarus deformity of feet; thoracolumbar scoliosis, distinctive facial features distinctive facial features otitis media with effusions (requiring tympanostomy); distinctive facial features premature eruption of teeth; distinctive facial features distinctive facial features facial asymmetry; premature eruption of teeth; puberty at 12; male pattern baldness by age 17; distinctive facial features severe bilateral planovalgus; nocturnal eneuresis; distinctive facial features 5/6 (83%) limb abnormalities; 2/4 males (50%) cryptorchidism; 1/6 (17%) scoliosis; 2/6 (33%) hypopituitarism; 6/6 hyperteloric (100%); 4/6 median facial cleft 67%); 4/6 cleft palate (67%)

Abbreviations: AFO, ankle foot orthoses; ASD, autism or autism spectrum disorder; DN, de novo; WES, whole-exome sequencing; GM, gross motor; GERD, gastro-esophageal reflux disease; WGS, whole-genome sequencing; GTC, generalized tonic-clonic; ID, intellectual disability; IS, infantile spasms; mo, months; MRI, magnetic resonance imaging; ND, not done; NR, not relevant; NT, not tested; OFC, occipital frontal circumference; PECS, picture exchange communication system; SS, Sanger sequencing; yr, year.

a

Mildly affected mother with mosaicism and fetus terminated at 20 weeks excluded.

b

Not inherited from mother, not present in either of two unaffected brothers, father not available for testing.